Last updated: February 22, 2026
What is NDC 55111-0629?
NDC 55111-0629 refers to a biologic product currently marketed under the brand name Orencia (abatacept). It is a recombinant fusion protein approved for rheumatoid arthritis and psoriatic arthritis. The drug is available in both intravenous (IV) and subcutaneous (SC) formulations.
Market Overview
The global rheumatoid arthritis (RA) treatment market reached approximately $23 billion in 2022, with biologics accounting for over 70% of market share. Orencia is competitively positioned among other biologics such as Humira (adalimumab), Enbrel (etanercept), and Stelara (ustekinumab).
Key Market Drivers:
- Growing prevalence of RA, estimated at 0.5-1% worldwide.
- Increased adoption of biologics for disease control.
- Patent exclusivity extending through 2028, delaying biosimilar competition.
- Ageing population leading to higher incidence of autoimmune diseases.
Competitive Landscape:
| Product |
Class |
Market Share (2022) |
Price per 1 Vial (USD) |
Patent Status |
| Orencia (abatacept) |
CTLA-4 fusion protein |
12% |
$4,200 |
Patent until 2028 |
| Humira (adalimumab) |
Anti-TNF agent |
35% |
$2,500 |
Biosimilar entry from 2023 |
| Enbrel (etanercept) |
Anti-TNF agent |
15% |
$2,700 |
Patent expired in 2028 |
| Stelara (ustekinumab) |
IL-12/23 inhibitor |
10% |
$5,200 |
Patent until 2025 |
Price Projection Analysis
Current Pricing Dynamics
Orencia's average retail price per syringe (SC) is $4,200, with a typical dose of 125 mg administered weekly. The IV formulation ranges from $4,000 to $6,000 per infusion, depending on dosage and region.
Market Trends Affecting Future Pricing
- Biosimilar Competition: Entry of biosimilars expected from 2023-2028 will exert downward pricing pressure.
- Patent Expiration: Patent expiry in 2028 will accelerate generic and biosimilar entries, likely decreasing prices by 40-60%.
- Reimbursement Policies: Increased focus on value-based pricing and prior authorization will influence net prices.
Price Projection (Next Five Years)
| Year |
Estimated Price per Dose (USD) |
Notes |
| 2023 |
$4,100 |
Stabilization; biosimilar competition begins |
| 2024 |
$3,500 |
Biosimilars gaining market share; price erosion |
| 2025 |
$3,000 |
Increased biosimilar penetration; price pressure |
| 2026 |
$2,500 |
Significant biosimilar entry; generic availability |
| 2027 |
$2,200 |
Continued price decline; margin compression |
Assumptions:
- Biosimilar adoption grows at 15-20% annually post-2023.
- Price erosion approximates 10-15% annually following biosimilar entry.
- Regulatory and payer policies shape price stability and discounts.
Sales Forecast
Projected sales volume will depend on adoption rates within the RA market, with global sales estimated at $300 million in 2022. With expected market penetration and price reductions, sales could decline slightly or stabilize, depending on market share retention.
| Year |
Sales Volume (units) |
Approximate Sales (USD) |
Market Share |
| 2022 |
70,000 |
$300 million |
12% of biologics |
| 2023 |
75,000 |
$310 million |
Slight increase due to existing patient base |
| 2024 |
68,000 |
$238 million |
Decline driven by biosimilar competition |
| 2025 |
65,000 |
$195 million |
Market consolidation continues |
| 2026 |
60,000 |
$150 million |
Biosimilar dominance increases |
Regulatory and Policy Impact
- Patents expire in 2028, opening biosimilar market for abatacept.
- Regulatory pathways in Europe and the US streamline biosimilar approvals, encouraging cost competition.
- Payer policies favor cost-effective biologics, further pressuring pricing.
Key Market Opportunities and Risks
Opportunities:
- Expansion into new indications such as juvenile idiopathic arthritis.
- Differentiation through biosimilar development and pricing strategies.
- Focus on personalized medicine and patient adherence.
Risks:
- Accelerated biosimilar entry reducing market share and price.
- Regulatory hurdles or shifts in reimbursement favoring generics.
- Competitive advances from new biologics or oral targeted therapies.
Summary
By 2028, the price of NDC 55111-0629 (Orencia) is expected to decline by approximately 50%, driven primarily by biosimilar competition. Market share will likely stabilize around 8-12%, with sales volume influenced by market penetration and approval of expanded indications. Strategic positioning prior to patent expiry is critical for maintaining revenue streams.
Key Takeaways
- The biologic's market value is sizable but faces significant price and volume pressure post-2028.
- Pricing declines forecast at 10-15% annually following biosimilar entry.
- Revenue stability hinges on market share retention, indication expansion, and cost management strategies.
- Biosimilar competition from 2023 onwards will be a major determinant of market dynamics.
- Regulatory policies and payer behavior will influence future pricing and market access.
FAQs
-
When will biosimilars for NDC 55111-0629 likely enter the market?
Biosimilars are expected to launch after patent expiry in 2028, although certain biosimilars may be approved earlier depending on regulatory processes.
-
What is the main driver behind the price decline for this biologic?
Biosimilar competition and patent expiration operate as primary drivers, resulting in decreased prices as market share shifts.
-
How does the current pricing compare with peers?
Orencia's current price per dose is higher than anti-TNF agents like Humira but comparable to other fusion proteins like Stelara.
-
Will the drug's sales volume increase or decrease in the coming years?
Sales volume may decline due to biosimilar market entry but could stabilize if market share is maintained through differentiated indications and patient management.
-
What factors could accelerate or slow down the price decline?
Factors include regulatory approval times for biosimilars, payer acceptance, and how aggressively biosimilar manufacturers price their products.
References
[1] Evaluate Pharma. (2023). Global biologic market report.
[2] IQVIA. (2022). Global Oncology and Rheumatology Market Data.
[3] U.S. Food and Drug Administration. (2022). Biosimilar approval pathways.
[4] Biosimilar Implementation Guidelines. (2023). Health Policy Institute.
[5] World Health Organization. (2022). Autoimmune disease prevalence and epidemiology.
